Page last updated: 2024-12-07

gamma-carboline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gamma-carboline: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID130802
CHEMBL ID12540
CHEBI ID182291
SCHEMBL ID121401
SCHEMBL ID4127392
MeSH IDM0156405

Synonyms (41)

Synonym
5h-pyrido(4,3-b)indole
89407ep2he ,
unii-89407ep2he
nsc 160470
CHEBI:182291
inchi=1/c11h8n2/c1-2-4-10-8(3-1)9-7-12-6-5-11(9)13-10/h1-7,13
smr000841382
MLS001242827
OPREA1_254173
5h-pyrido[4,3-b]indole
nsc160470
244-69-9
nsc-160470
.gamma.-carboline
gamma-carboline
gama-carboline
CHEMBL12540 ,
g-carboline
NCGC00247392-01
STL257072
HMS2216C05
AKOS015966923
3-azarbazole
.gamma.-carboline [mi]
3-azacarbazole
SCHEMBL121401
RDMFHRSPDKWERA-UHFFFAOYSA-N
pyrido[4,3-b]indole
SCHEMBL4127392
DTXSID80179147
mfcd00965976
CS-W006474
DS-5456
P2362
AMY19431
5-carboline
Q27269991
SB66876
SY055394
bdbm50572080
Z1255438954

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" During the 5-day predation stress paradigm, oral drug treatment over a period of 2 weeks at the higher dosage regimen decreased anxiety-like behaviour."( Pro-neurogenic, Memory-Enhancing and Anti-stress Effects of DF302, a Novel Fluorine Gamma-Carboline Derivative with Multi-target Mechanism of Action.
Aksinenko, A; Bachurin, S; Bahzenova, N; Fisenko, V; Grigoriev, V; Lesch, KP; Lillesaar, C; Markova, N; Redkozubova, O; Schmitt-Böhrer, AG; Serkova, T; Shevtsova, E; Sokolov, V; Strekalova, T; Trofimov, A; Umriukhin, A; Vinogradova, D; Zamoyski, V, 2018
)
0.71
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyridoindole
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Ki250.00000.00020.561410.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Ki250.00000.00020.635210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki250.00000.00020.621710.0000AID40666
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)21.40000.00000.933210.0000AID1766053
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Ki250.00000.00020.675810.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki250.00000.00020.646910.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Ki250.00000.00020.671210.0000AID40666
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki250.00000.00020.557710.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Ki250.00000.00020.640310.0000AID40666
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Ki250.00000.00020.570810.0000AID40666
CholinesteraseEquus caballus (horse)IC50 (µMol)1.20000.00002.22149.4000AID1766056
GABA theta subunitRattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Ki250.00000.00020.656110.0000AID40666
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1766052Inhibition of human GluN1-1a/NR2B receptor expressed in transgenic mouse fibroblast cells assessed as inhibition of L-glutamate-induced excitotoxicity at 20 uM by measuring LDH activity by cell based assay2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1766056Inhibition of recombinant equine BChE by Ellman's method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID40666In vitro inhibition of [3H]diazepam binding to benzodiazepine receptor in rat cerebral cortical membrane1982Journal of medicinal chemistry, Sep, Volume: 25, Issue:9
Beta-carbolines: synthesis and neurochemical and pharmacological actions on brain benzodiazepine receptors.
AID1766053Inhibition of recombinant human AChE expressed in HEK293 cells by Ellman's method2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1766050Inhibition of human GluN1-1a/NR2A receptor expressed in transgenic mouse fibroblast cells assessed as inhibition of L-glutamate-induced excitotoxicity at 50 uM by measuring LDH activity by cell based assay2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID1766059Solubility of the compound at >= 50 uM2021Bioorganic & medicinal chemistry, 09-15, Volume: 46Evaluation of γ-carboline-phenothiazine conjugates as simultaneous NMDA receptor blockers and cholinesterase inhibitors.
AID318336Antiviral activity against BVDV infected in MDBK cells assessed as reduction in viral induced cell destruction by MTT assay2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Gamma-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity.
AID318337Cytotoxicity against mock-infected MDBK cells by LDH method2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Gamma-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity.
AID318339Growth inhibition of human HL60 cells2008Bioorganic & medicinal chemistry, Apr-01, Volume: 16, Issue:7
Gamma-carboline derivatives with anti-bovine viral diarrhea virus (BVDV) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (7.14)18.7374
1990's1 (2.38)18.2507
2000's6 (14.29)29.6817
2010's24 (57.14)24.3611
2020's8 (19.05)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.73 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index27.14 (26.88)
Search Engine Supply Index3.63 (0.95)

This Compound (23.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other42 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]